Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Revenue:        
Contract research revenue $ 44,906 $ 0 $ 59,875 $ 0
Costs and Expenses:        
Research and development 2,314,716 642,576 4,698,934 1,564,287
General and administrative 1,706,493 977,653 3,824,468 2,293,430
Total costs and expenses 4,021,209 1,620,229 8,523,402 3,857,717
Loss from operations (3,976,303) (1,620,229) (8,463,527) (3,857,717)
Other income/(expense), net 8,663 (3,656) (230) (10,778)
Net loss (3,967,640) (1,623,885) (8,463,757) (3,868,495)
Inducement charge from exercise of warrants     (16,741,356) 0
Net loss attributable to common shareholders $ (3,967,640) $ (1,623,885) $ (25,205,113) $ (3,868,495)
Net loss available for common shareholders per share - basic and diluted $ (0.04) $ (0.03) $ (0.29) $ (0.07)
Weighted average common shares outstanding:        
Basic and diluted 91,611,531 57,593,414 88,285,929 57,440,685